Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The tonic-clonic seizures treatment market is expected to grow at a CAGR of 6% during the forecast period of 2024-2032, driven by the increased research activities and clinical trials aimed at finding new treatments and the rising introduction of generic treatment options for tonic-clonic seizures.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Tonic-clonic seizures, also called grand mal seizures, refer to a type of generalized seizure that affects the entire brain of the individual. Tonic-clonic seizures combine the characteristics of tonic and clonic seizures, as the name implies. Tonic refers to stiffening, while clonic refers to rhythmical jerking. For the diagnosis of the tonic-clonic, the medical history is reviewed prior to the tests such as neurological exams, blood tests, electroencephalogram (EEG), computerized tomography (CT) scan, and others. The continued cooperation of many organizations and governments in the fight against the stigma associated with epilepsy and seizures has resulted in increased awareness and a corresponding increase in demand for treatment.
Increased clinical trial activity has resulted in a stronger product pipeline, which is contributing to market growth. Technological advancements and increased investments in R&D activities have paved the way for a variety of novel treatment options. Furthermore, increased healthcare budget and spending and improved healthcare infrastructure are expected to support market growth over the forecast period.
Increasing Availability of Generic Medications for Tonic-Clonic Seizures to Support Market Growth
The market is witnessing an increased availability of generic drugs, which are generally less expensive than the branded versions. For instance, in July 2024 , the global pharmaceutical company, Lupin, announced that it had received approval for its Abbreviated New Drug Application (ANDA) for Topiramate Extended-Release Capsules from the United States Food and Drug Administration (U.S. FDA). The company will manufacture and market Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, and 200 mg, which is a generic version of Trokendi XR Extended-Release Capsules, 25 mg, 50 mg, 100 mg, and 200 mg, developed by Supernus Pharmaceuticals. This generic medication is indicated for partial-onset or primary generalized tonic-clonic seizures in patients (aged 6 years of age or above) and will be produced at Lupin’s Pithampur facility in India.
Thus, the increasing introduction of generic options is expected to improve treatment accessibility and also drive market growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Increasing Research and Clinical Trials to Affect the Market Landscape
The market is witnessing an increase in research activities and clinical trials aimed at finding new treatments and improving existing therapies for tonic-clonic seizures. These research initiatives are supported by increased investment from research institutions and pharmaceutical companies in order to develop innovative treatments and evaluate their effectiveness through clinical trials. This rising focus on research for tonic-clonic seizures is expected to fuel market growth.
Growing Focus on Combination Therapies to Augment Tonic-Clonic Seizures Treatment Market Demand
The increased focus on combination therapies is a significant trend that is likely to bolster the market demand. Combination therapies are increasingly adopted by patients who do not respond well to monotherapy. This treatment strategy targets multiple pathways involved in seizure generation, which often results in better clinical outcomes. In addition, combination therapy is widely prescribed for patients who develop resistance to a single anti-epileptic drug.
Rising Awareness Campaigns to Elevate the Tonic-Clonic Seizures Treatment Market Value
In June 2024 , a charitable organization in England and Wales, Epilepsy Action (British Epilepsy Association), launched its first TV ad campaign featuring a first-aid video on how to help someone who is having a tonic-clonic seizure. This initiative was directed at raising awareness about epilepsy and tonic-clonic seizure aid. Such awareness initiatives and educational programs are expected to contribute to earlier diagnosis and treatment, which is likely to elevate the market value in the coming years.
Adoption of Advanced Anti-Seizure Medications to Influence Tonic-Clonic Seizures Treatment Market Dynamics
One of the major trends in the market is the growing adoption of novel anti-seizure medications that are linked with improved efficacy and safety profiles compared to traditional treatment options. The popularity of medications such as levetiracetam, lamotrigine, and lacosamide is rising in the market due to their better tolerability and fewer side effects. In addition, the development of anti-seizure drugs that target specific seizure mechanisms is projected to aid market expansion.
Market Breakup by Drug Class
Market Breakup by Drug Generation
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Region
Drug Class Segment Represents a Major Market Share
The market is segmented by drug class into barbiturates, hydantoin, phenyltriazine, iminostilbenes, and others. The market value of this segment is influenced by the introduction of new drugs and changes in treatment guidelines. The hydantoin segment is experiencing significant demand in the market and is commonly prescribed as a first-line treatment for tonic-clonic seizures. The efficacy of hydantoins such as the phenytoin drug in controlling seizures and the established safety drives their popularity in the market.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
In the United States, the market is driven by the increasing prevalence of epilepsy and the availability of advanced treatment options. The strong presence of pharmaceutical companies and a well-established healthcare infrastructure also support market expansion. The market also benefits from the rising adoption of newer antiepileptic drugs and growing awareness about seizure treatment. Further, increased focus on the development of novel therapeutics for tonic-clonic seizures is expected to fuel the growth in this regional market.
The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
GSK Group
Global healthcare company GSK (GlaxoSmithKline plc) has a significant presence in the market and offers medications indicated for epilepsy, including drugs targeting tonic-clonic seizures. One of their key drugs is Lamotrigine (Lamictal) which helps to treat tonic-clonic seizures.
Eisai Co. Ltd.
Headquartered in Tokyo, Japan, this Japanese pharmaceutical company has a strong portfolio in the neurology market including tonic-clonic seizure treatment. Its anti-epileptic drug (AED) Fycompa® is used for the treatment of partial-onset seizures and primary generalized tonic-clonic seizures.
Catalyst Pharmaceutical Co. Ltd.
Biopharmaceutical company Catalyst Pharmaceutical Co. Ltd. is based in Coral Gables, Florida. The company specializes in the development and commercialization of innovative therapies for rare neurological diseases, including epilepsy and other seizure disorders.
Otsuka Pharmaceutical Co. Ltd.
Japanese pharmaceutical company Otsuka Pharmaceutical Co. Ltd. is one of the leading players in the market and enjoys a strong presence in the neurology sector. Its anti-epileptic medication E Keppra® (generic name: levetiracetam) is widely used for treating tonic-clonic and other types of seizures.
Other key players in the market include Prasco LLC, UCB Japan Co. Ltd., Pfizer Inc., Azurity Pharmaceuticals Inc., and GL Pharma.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Drug Class |
|
Breakup by Drug Generation |
|
Breakup by Route of Administration |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
Share